Intellectual Property

Spring came in like a lamb in the NPE world. NPE activity was light in April.* Frequent filers included Adaptive Avenue Associates, Advanced Transactions, Communication Interface Technologies, Innovaport, Linfo IP, and SITO Mobile R&D IP.

As usual, I prepared the report in partnership with and using Docket Navigator and its powerful database. Docket Navigator is

Earlier this month, FDA approved Boehringer Ingelheim’s high-concentration (100 mg/mL), citrate-free formulation, CYLTEZO (adalimumab-adbm), a biosimilar to Humira (adalimumab).  CYLTEZO was first approved in the US in 2017 and later approved in the US as an interchangeable biosimilar to Humira in October 2021.  A lower concentration version of CYLTEZO (50 mg/mL) has been on the

Introduction:
In the UAE, community living is a common lifestyle choice, encouraging a sense of togetherness and shared experiences. However, this closeness to neighbors can sometimes lead to challenges, especially concerning the safeguarding of privacy and the peaceful enjoyment of one’s property.
Fortunately, UAE laws provide mechanisms to safeguard individuals from privacy violations and nuisances